Head-to-head evidence
Brolucizumab-Dbll vs Surabgene Lomparvovec (ABBV-RGX-314)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Brolucizumab-Dbll
Marketed by Novartis
NCT05672979 · Phase 3 · status unknown
This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.
Surabgene Lomparvovec (ABBV-RGX-314)
Developed by AbbVie and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · Surabgene Lomparvovec (ABBV-RGX-314)'s landscape